Human medicines European public assessment report (EPAR): Abrysvo, Respiratory syncytial virus vaccines, Respiratory Syncytial Virus Infections, Date of authorisation: 23/08/2023, Status: Authorised
Abrysvo is a vaccine for protecting against lower respiratory tract disease (LRTD; diseases of the lungs such as bronchitis or pneumonia) caused by respiratory syncytial virus (RSV) in adults 60 years of age and older.
It is also for use in mothers during pregnancy to protect their infants against LRTD from birth through 6 months of age.
Abrysvo contains versions of two proteins found on the surface of the virus called RSV subgroup A stabilised prefusion F and RSV subgroup B stabilised prefusion F.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
